-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AND-017 in Anemia in Chronic Kidney Disease (Renal Anemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AND-017 in Anemia in Chronic Kidney Disease (Renal Anemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AND-017 in Anemia in Chronic Kidney...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aglatimagene Besadenovec in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aglatimagene Besadenovec in Pancreatic Ductal Adenocarcinoma Drug Details: Aglatimagene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mirdametinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mirdametinib in Solid Tumor Drug Details: mirdametinib (PD-0325901) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efgartigimod Alfa in Antibody-Mediated Rejection (AMR)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Antibody-Mediated Rejection (AMR) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efgartigimod Alfa in Antibody-Mediated Rejection (AMR) Drug Details: Efgartigimod...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegargiminase in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Non-Small Cell Lung Cancer Drug Details: Pegargiminase...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Epcoritamab in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Epcoritamab in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Epcoritamab in Lymphoma Drug Details: Epcoritamab-Bysp (Epkinly / Tepkinly) is a monoclonal...
-
Product Insights
NewNet Present Value Model: SQZ Biotechnologies Co’s SQZ-AAC- HPV
Empower your strategies with our Net Present Value Model: SQZ Biotechnologies Co's SQZ-AAC- HPV report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: SQZ Biotechnologies Co’s SQZ-AAC- HPV
Empower your strategies with our Net Present Value Model: SQZ Biotechnologies Co's SQZ-AAC- HPV report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-125 in Retinitis Pigmentosa (Retinitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-125 in Retinitis Pigmentosa (Retinitis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 4D-125 in Retinitis Pigmentosa (Retinitis) Drug Details: 4D-125 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varlitinib in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Varlitinib in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varlitinib in Breast Cancer Drug Details: ASLAN-001 (varlitinib) is under development for...